Despite success in some cancer patients, a drug that neutralizes GDF-15 was clearly harmful in HF patients. The question is, why?

In postmenopausal women with type 2 diabetes, oral hormone replacement therapy (HRT) may increase the risk of CV events. Presenting data from a real-world study at the recent European Association for ...

The most-read article this month was a look at the new European valve guidelines, with the list fleshed out by news from ESC 2025.

The data aren’t definitive, but continuing OAC or switching to another drug doesn’t seem to be enough for this high-risk group.

The Integra-D trial shows the device, which provides cardiac contractility modulation and defibrillation, also eases symptoms.

Vocal monitoring has the potential to identify HF patients with worsening congestion early and prevent acute decompensation.

The new SCAI initiative brings optimism for a population that has seen little innovation or changes to treatment paradigms in years.

It’s meant to support the valve guidelines and aid in disentangling the complexities of the tricuspid field, one of the authors says.

The trial’s findings will dampen enthusiasm for the drug in stroke recovery, though research questions remain, one expert says.

In 2023, there were 437 million disability-adjusted life-years lost from cardiovascular disease, up from 320 million in 1990.

The drug met primary safety and efficacy outcomes, with full results to be presented at the AHA Scientific Sessions.

Implanting pacemakers in those who meet criteria for prophylactic use appears to be overtreating some patients.